Grifols (GIKLY) Cash & Current Investments (2009 - 2025)
Grifols (GIKLY) posted Cash & Current Investments of $965.0 million for Q4 2025, down 8.41% quarter-over-quarter from $1.1 billion in Q4 2024, and down 8.41% year-on-year from $1.1 billion in Q4 2024.
Grifols (GIKLY) Cash & Current Investments (2009 - 2025) Analysis & Trends
Grifols (GIKLY) has reported Cash & Current Investments for 16 consecutive years, with $965.0 million the latest figure, recorded in Q4 2025.
- Cash & Current Investments for Q4 2025 came in at $965.0 million, down 8.41% year-over-year; the trailing twelve-month figure through Dec 2025 was $965.0 million (down 8.41% YoY), and the FY2025 annual result was $965.0 million, down 8.41% from the prior year.
- Cash & Current Investments was $965.0 million for Q4 2025 at Grifols, down from $1.1 billion in the prior quarter.
- Over five years, Cash & Current Investments peaked at $5.4 billion in Q4 2021 and troughed at $594.6 million in Q4 2023.
- Average Cash & Current Investments over 5 years is $1.7 billion, with a median of $965.0 million recorded in 2025.
- Year-over-year, Cash & Current Investments jumped 678.94% in 2021 and sank 88.77% in 2022.
- Over 5 years, Cash & Current Investments stood at $5.4 billion in 2021, then tumbled by 88.77% to $604.7 million in 2022, then declined by 1.66% to $594.6 million in 2023, then soared by 77.2% to $1.1 billion in 2024, then decreased by 8.41% to $965.0 million in 2025.
- Per Business Quant data, the three most recent Cash & Current Investments figures were $965.0 million in Q4 2025, $1.1 billion in Q4 2024, and $594.6 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 5.28 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 22.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 9.39 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 7.94 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 5.70 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 7.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 13.08 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 100.00 Mn |
| 10 | Grifols | - | - | - | 964.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 964.99 Mn |
| Dec 31, 2024 | 1.05 Bn |
| Dec 31, 2023 | 594.61 Mn |
| Dec 31, 2022 | 604.66 Mn |
| Dec 31, 2021 | 5.38 Bn |
| Dec 31, 2020 | 691.11 Mn |
| Dec 31, 2019 | 2.74 Bn |
| Dec 31, 2018 | 1.20 Bn |
| Dec 31, 2017 | 1.06 Bn |
| Dec 31, 2016 | 969.15 Mn |
| Dec 31, 2015 | 1.25 Bn |
| Dec 31, 2014 | 1.35 Bn |
| Dec 31, 2013 | 966.34 Mn |
| Sep 30, 2013 | 647.68 Mn |
| Jun 30, 2013 | 626.65 Mn |
| Mar 31, 2013 | 535.36 Mn |
| Dec 31, 2012 | 614.45 Mn |
| Sep 30, 2012 | 501.99 Mn |
| Jun 30, 2012 | 438.91 Mn |
| Mar 31, 2012 | 254.57 Mn |